QNTM (QNTM) Stock Price & Analysis

QNTM (QNTM) fell 3.95% to USD 3.89 as of June 10, 2026 at 00:51 UTC, according to Nexqual real-time market data.

QNTM last closed at USD 4.05; the session ranged USD 3.59–4.1 on volume of 320,319 shares. Market capitalization is $24.89M, with a 52-week range of USD 2.07–38.25 (NCM). Source: Nexqual, June 10, 2026 at 00:51 UTC.

Key Statistics (as of June 10, 2026 at 00:51 UTC)

PriceUSD 3.89
Change▼ 3.95% (down)
Previous CloseUSD 4.05
OpenUSD 4.07
Day RangeUSD 3.59 – 4.1
52-Week RangeUSD 2.07 – 38.25
Volume320,319 shares
Market Cap$24.89M
ExchangeNCM

Technical Analysis (QNTM)

Nexqual's technical model rates QNTM "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:51 UTC.

Overall SignalSELL
RSI (14)39.62 (neutral)
vs SMA50Below (USD 4.97)
MACD-0.26 (negative)

Analyst Ratings (QNTM)

Wall Street analysts rate QNTM "None" based on 1 analysts, with a mean price target of USD 12.5 (range USD 12.5–12.5), per Nexqual as of June 10, 2026 at 00:51 UTC.

Consensus RatingNone
Analyst Count1
Mean TargetUSD 12.5
High TargetUSD 12.5
Low TargetUSD 12.5
Buy / Hold / Sell1 / 0 / 0

Earnings (QNTM)

Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-03-31USD -4.17 vs est -0.68 ▼ miss
2025-09-30USD -1.77 vs est -3.7 ▲ beat

Source: Nexqual, June 10, 2026 at 00:51 UTC.

Financials & Fundamentals (QNTM)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-2056.51%
Current Ratio0.63
Total Cash$4.56M
Total Debt$870,057
Free Cash Flow$2.16M

Source: Nexqual, June 10, 2026 at 00:51 UTC.

Financial Health Score (QNTM)

Nexqual rates QNTM's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:51 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetMixed — $5M cash, no debt
Cash FlowWeak — Operating cash flow -$6M
EfficiencyCritical — ROE -2057%, ROA -62.4%

Ownership (QNTM)

Insider Ownership+12.36%
Institutional Ownership+9.86%
Shares Outstanding6.40M
Float5.93M
Short % of Float+3.82%

Source: Nexqual, June 10, 2026 at 00:51 UTC.

Leadership (QNTM)

QNTM is led by Zeeshan Saeed (age 55), Co-Founder, CEO & Executive Non-Independent Co-Chairman, per Nexqual as of June 10, 2026 at 00:51 UTC.

Co-Founder, CEO & Executive Non-Independent Co-ChairmanZeeshan Saeed (age 55)
Co-Founder & Executive Non-Independent Co-ChairmanAnthony John Durkacz (age 49)
Chief Financial OfficerDonal Carroll (age 48)
Vice President of Clinical & Scientific AffairsAndrzej Chruscinski
Director of Pharmaceutical DevelopmentAshwini Joshi M.S.

Major Backers & Investors (QNTM)

Notable institutional backers of QNTM include AdvisorShares Trust-AdvisorShares Psychedelics ETF, AdvisorShares Investments, LLC, Platform Technology Partners, according to Nexqual as of June 10, 2026 at 00:51 UTC.

Active Investors

InvestorStake
AdvisorShares Trust-AdvisorShares Psychedelics ETF4.31%
AdvisorShares Investments, LLC2.84%
Platform Technology Partners1.08%
Jane Street Group, LLC0.83%
Citadel0.42%
Marex Group Plc0.35%
Virtu Financial LLC0.32%
Mariner, LLC0.26%

Source: Nexqual, June 10, 2026 at 00:51 UTC.

Peers & Related Stocks

SymbolNamePriceChange
SEGSeaport Entertainment Group IncUSD 24.08▲ 0.58%
AIFFFirefly Neuroscience, Inc.USD 1.61▲ 1.9%
APMAptorum Group LimitedUSD 1.12▲ 10.89%
JTAIJet.AI Inc.USD 7.81▲ 2.76%
DWTXDogwood Therapeutics, Inc.USD 1.45▼ 3.33%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:51 UTC. This page is informational and not investment advice.